Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to $1.3 million.

  • Heron Therapeutics' Free Cash Flow fell 54.73% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.1 million, marking a year-over-year decrease of 246.99%. This contributed to the annual value of -$24.2 million for FY2024, which is 59.83% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Free Cash Flow is $1.3 million, which was up 112.02% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Free Cash Flow ranged from a high of $2.9 million in Q3 2024 and a low of -$63.3 million during Q2 2021.
  • For the 3-year period, Heron Therapeutics' Free Cash Flow averaged around -$9.3 million, with its median value being -$9.5 million (2024).
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Free Cash Flow was 129.48% (2024), while the steepest drop was 663.17% (2024).
  • Over the past 5 years, Heron Therapeutics' Free Cash Flow (Quarterly) stood at -$45.6 million in 2021, then grew by 16.87% to -$37.9 million in 2022, then spiked by 105.81% to $2.2 million in 2023, then tumbled by 663.17% to -$12.4 million in 2024, then slumped by 54.73% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$11.1 million for Q2 2025, and -$9.0 million during Q1 2025.